Literature DB >> 9234532

DNA vaccination for the induction of immune responses against hepatitis C virus proteins.

G Inchauspé1, M E Major, I Nakano, L Vitvitski, C Trépo.   

Abstract

Recent analysis of clinical and experimental cases of hepatitis C virus (HCV) infection suggest the possible role of the viral nucléocapsid (C), the nonstructural protein 3 (NS3) and the envelope glycoproteins E1 and/or E2 in the mounting of immune responses capable to control infection (Botarelli et al., Gastroenterology, 1993, 104, 580-587; Choo et al., Proc. Natl Acad. Sci. USA, 1994, 91, 1294-1298). We have used DNA-based immunization to study the immune responses that can be induced by injecting DNA-derived immunogens encoding C and E2 sequences. Comparative analysis were performed in mice using expression plasmids containing full-length or partial gene sequences cloned in fusion with the hepatitis B virus surface antigen (HBV-HCV chimeras). The results obtained indicate that: (1) anti-C and anti-E2 antibodies can be induced with all constructs including the HBV-HCV chimeras; (2) titers range from 1:100 to 1:100000 depending on the antigen and nucleotide sequence context; (3) all HCV DNA immunogens are associated with a predominant Th1 response; (4) CTL can be detected against both HCV and HBV determinants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234532     DOI: 10.1016/s0264-410x(96)00275-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

3.  The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB/c mice.

Authors:  Wenbo Zhu; Yanzi Chang; Chunchen Wu; Qingxia Han; Rongjuan Pei; Mengji Lu; Xinwen Chen
Journal:  Clin Vaccine Immunol       Date:  2010-06-02

4.  Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.

Authors:  Jin-Won Youn; Yu-Wen Hu; Nancy Tricoche; Wolfram Pfahler; Mohamed Tarek Shata; Marlene Dreux; François-Loic Cosset; Antonella Folgori; Dong-Hun Lee; Betsy Brotman; Alfred M Prince
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

5.  Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo.

Authors:  Wenbo Zhu; Chunchen Wu; Wanyu Deng; Rongjun Pei; Yun Wang; Liang Cao; Bo Qin; Mengji Lu; Xinwen Chen
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

6.  Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model.

Authors:  Rama Jayaraj; David Piedrafita; Terry Spithill; Peter Smooker
Journal:  Genet Vaccines Ther       Date:  2012-08-31

7.  The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response.

Authors:  Juris Jansons; Irina Sominskaya; Natalia Petrakova; Elizaveta S Starodubova; Olga A Smirnova; Ekaterina Alekseeva; Ruta Bruvere; Olesja Eliseeva; Dace Skrastina; Elena Kashuba; Marija Mihailova; Sergey N Kochetkov; Alexander V Ivanov; Maria G Isaguliants
Journal:  Cells       Date:  2019-02-28       Impact factor: 6.600

8.  Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade.

Authors:  Cheng J Ma; Jun P Ren; Guang Y Li; Xiao Y Wu; Dirk G Brockstedt; Peter Lauer; Jonathan P Moorman; Zhi Q Yao
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.